Medical Technology

SHERIDAN, WYOMING – May 5, 2025 – Medtronic plc (NYSE: MDT), a global leader in healthcare technology, has received U.S. Food and Drug Administration (FDA) approval for the OmniaSecure™ defibrillation lead—the smallest-diameter, catheter-delivered defibrillation lead for right ventricular implantation. This approval marks a major advancement in cardiac rhythm management, offering physicians a less invasive, highly durable solution to treat life-threatening arrhythmias in both adults and adolescents with smaller anatomies.

SHERIDAN, WYOMING – May 5, 2025 – Medtronic has announced a major milestone for its Hugo™ robotic-assisted surgery (RAS) system, as the Expand URO U.S. clinical trial met both primary safety and effectiveness endpoints. The results position the company for strategic market entry into the U.S. robotic-assisted surgery sector, the largest of its kind globally, and were presented as a late-breaking session at the American Urologic Association (AUA) annual meeting in Las Vegas.

Landmark Trial Sets New Benchmark in Robotic Urologic Surgery

SHERIDAN, WYOMING – May 5, 2025 – Medtronic plc (NYSE: MDT) has announced encouraging one-year clinical outcomes for its investigational Affera™ pulsed field ablation (PFA) technologies, reinforcing its strategic leadership in arrhythmia management.